The Medical News

The Medical News

The U.S. Food and Drug Administration has approved an artificial pancreas system - based on technology from the University of Virginia Center for Diabetes Technology - that automatically monitors and regulates blood glucose levels. We are excited that our decade-long research, which recently culminated in a large-scale clinical trial published in the New England Journal of Medicine , has been successfully translated to the clinical practice. This is a new-generation interoperable automated glucose control system, which allows seamless integration of a continuous glucose sensor, insulin pump, and a smart control algorithm". Boris Kovatchev, PhD, director of the UVA center The artificial pancreas system, called Control-IQ and manufactured by Tandem Diabetes Care, tracks blood glucose levels with a continuous glucose monitor (Dexcom G6 CGM) and automatically delivers the hormone insulin as needed. The system frees people from testing their blood sugar levels multiple times a day by fingerstick, and from delivery of insulin by multiple daily injections. Better managing type 1 diabetes The pump is programmed with an algorithm developed at UVA that uses glucose monitoring information to adjust the recipient's insulin dose automatically. FDA approval follows results from a multicenter clinical trial published in the New England Journal of Medicine that found the new artificial pancreas system was more effective than existing treatments at controlling blood glucose levels in people with type 1 diabetes . The study showed that the system improved blood glucose control throughout the day and overnight. During the study, 168 participants age 14 or older with type 1 diabetes were randomly assigned to use either the artificial pancreas system or sensor-augmented pump (SAP) therapy with a continuous glucose monitor and insulin pump that did not automatically adjust insulin throughout the day. Related Stories



Also in Industry News

How to decide whether or not to start treatment for prostate cancer?
How to decide whether or not to start treatment for prostate cancer?

0 Comments

How to decide whether or not to start treatment for prostate cancer?

Read More

Analysis of the SARS-CoV-2 proteome via visual tools
Analysis of the SARS-CoV-2 proteome via visual tools

0 Comments

Analysis of the SARS-CoV-2 proteome via visual tools

Read More

$65m investment increases British Patient Capital’s exposure to life sciences and health technology
$65m investment increases British Patient Capital’s exposure to life sciences and health technology

0 Comments

$65m investment increases British Patient Capital’s exposure to life sciences and health technology

Read More